---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Definition and etiology"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Definition and etiology. Topics: Definition: advanced non-neovascular AMD with well-demarcated atrophy of the RPE and choriocapillaris; Definition: confluent atrophy of photoreceptors, RPE, and choriocapillaris associated with scotoma; Bilateral and irreversible course of geographic atrophy; Terminology: geographic atrophy as a subset of complete RPE and outer retinal atrophy; 5 further topics. 9 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Definition: advanced non-neovascular AMD with well-demarcated atrophy of the RPE and choriocapillaris

> “The phenotype of GA, the advanced form of non-neovascular AMD, will have one or more zones of well-demarcated RPE and/or choriocapillaris atrophy. Drusen and other pigmentary abnormalities may surround the atrophic areas. Severe VA loss occurs more slowly in patients with GA than in patients with neovascular AMD. Geographic atrophy involving the foveal center causes approximately 10% of all AMD-related visual loss of 20/200 or worse.”
> “One or several well-demarcated zones of photoreceptor, RPE, and choriocapillaris atrophy. Drusen are usually present surrounding these zones and there may be surrounding pigment clumping. This is an advanced form of AMD when the center of the fovea is involved.”
> “Although an estimated 80% of patients with age-related macular degeneration (AMD) have non-neovascular or atrophic AMD, the neovascular form is responsible for most of the severe vision loss associated with AMD.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.1.1-2"></a>

### Definition: confluent atrophy of photoreceptors, RPE, and choriocapillaris associated with scotoma

> “GA, also known as ‘dry AMD’, is characterized by confluent atrophy of photoreceptors, RPE and choriocapillaris and is associated with scotoma.”

Source: [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)

> “In the late stages of AMD, 2 distinct manifestations emerge. One is the development of confluent areas of atrophy involving photoreceptors and retinal pigment epithelium, known as geographic atrophy.”

Source: [Fleckenstein et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12935482/)

<a id="topic-2.2.1.1-3"></a>

### Bilateral and irreversible course of geographic atrophy

> “Geographic atrophy (GA) is an advanced, vision-threatening form of age-related macular degeneration (AMD). This degenerative disease occurs with progressive loss of areas of the retinal pigment epithelium (RPE), photoreceptors, and underlying choriocapillaris.”
> “Loss of visual function because of GA is considered irreversible and usually bilateral, with half of patients developing GA in both eyes within seven years of the initial GA diagnosis.”

Source: [Boyer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5424580/)

<a id="topic-2.2.1.1-4"></a>

### Terminology: geographic atrophy as a subset of complete RPE and outer retinal atrophy

> “Geographic atrophy (GA) is a well-established end-stage manifestation of age-related macular degeneration (AMD).”
> “Thus, GA would be considered a subset of the more comprehensive term cRORA, with cRORA encompassing macular atrophy both with and without associated CNV.”

Source: [Sadda et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11366072/)

> “The advanced non-exudative form of AMD - as described by clinico-pathological correlations and high-resolution in-vivo imaging modalities - is typically characterized by well-defined patches lacking photoreceptors, by degeneration or complete loss of retinal pigment epithelium (RPE) as well as by loss or attenuation of the choriocapillaris layer”

Source: [Schmitz-Valckenberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5115977/)

<a id="topic-2.2.1.1-5"></a>

### Multifactorial etiology: ageing, genetic susceptibility, and smoking

> “AMD is a multifactorial disease related to aging, genetic susceptibility, and environmental risk factors such as cigarette smoking; it develops as a consequence of disruption of the normal homeostatic mechanisms of the retina.”

Source: [Fleckenstein et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12935482/)

> “Age-related macular degeneration is a multifactorial disorder, with dysregulation in the complement, lipid, angiogenic, inflammatory, and extracellular matrix pathways implicated in its pathogenesis. More than 50 genetic susceptibility loci have been identified, of which the most important are in the CFH and ARMS2 genes. The major non-genetic risk factors are smoking and low dietary intake of antioxidants (zinc and carotenoids).”

Source: [Mitchell et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30303083/)

<a id="topic-2.2.1.1-6"></a>

### Risk factors: age, family history, ancestry, and smoking

> “The main unmodifiable risk factors for the development of advanced AMD are increasing age, Northern European ancestry, and genetic factors. Although a number of modifiable risk factors have been investigated, cigarette smoking is the main one that has been consistently identified in numerous studies.”
> “Smoking significantly increases the risk of AMD and there appears to be a dose-response relationship, because the odds ratio increases with an increased number of pack-year exposure.”
> “Smoking cessation is associated with a reduced risk of AMD progression; the risk of developing AMD in individuals who have not smoked for more than 20 years is comparable to the risk in nonsmokers.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

> “The most important risk factors for GA are increasing age and family history.”

Source: [Bakri et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10408405/)

<a id="topic-2.2.1.1-7"></a>

### Risk factors: smoking intensity and incident AMD in prospective cohorts

> “Cigarette smoking is the most consistently reported environmental risk factor for AMD.”
> “In a large prospective cohort study of 61 862 women over a 12-year follow-up period, 1 case of AMD developed per 1708 person-years among women who currently smoked 25 or more cigarettes per day compared with 1 case per 3740 person-years among those who had never smoked.”

Source: [Fleckenstein et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12935482/)

<a id="topic-2.2.1.1-8"></a>

### Genetic risk: heritability and the CFH and ARMS2-HTRA1 loci

> “Estimated heritability of late-stage AMD is approximately 71%”
> “indicating that approximately 71% of the risk of AMD is genetic.”

Source: [Fleckenstein et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12935482/)

> “AMD genetics are unusual in that a small number of variants underlie a large proportion of heritability. The two loci with highest population attributable risk are CFH and ARMS2–HTRA1, and all other loci have low attributable risk, through low prevalence and/or weak association (with OR <1.2)”
> “Evidence shows that ARMS2–HTRA1 risk variants increase the risk of GA development and its accelerated enlargement. However, the C3 risk variant is specifically associated with slower GA enlargement but the CFH risk variants are not associated with altered speed of GA enlargement”

Source: [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)

> “Patients who are homozygous for the Y402H risk allele of CFH possess a 7.4-fold increased risk of AMD.”
> “Strong linkage disequilibrium has been shown across the ARMS2-HTRA1 region, and these two genes are also strongly associated with AMD.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.1.1-9"></a>

### Genetic risk: complement gene variants among late AMD susceptibility loci

> “Early genome-wide and targeted sequencing studies identified a common variant in the CFH gene associated with AMD risk (CFH Y402H)”
> “More recently, a meta-analysis and validation sequencing of GWAS data by the AMD Consortium, which evaluated >17,100 advanced AMD cases and >60,000 controls for common AMD risk variants, identified 19 single nucleotide polymorphisms (SNPs), of which four are contained within complement cascade genes (CFH, CFI, C3, C2/CFB).”

Source: [Boyer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5424580/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
